Jounce Therapeutics, Inc.
JNCE · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 204.8% | -56.8% | -57.8% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | $0 |
| % Margin | -61.2% | -338.4% | -72.4% | 35.7% |
| Net Income | -$0 | -$0 | -$0 | $0 |
| % Margin | -62.1% | -337.7% | -70.3% | 38.4% |
| EPS Diluted | -0.99 | -1.82 | -1.24 | 1.66 |
| % Growth | 45.6% | -46.8% | -174.7% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |